Respiratory syncytial virus bronchitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:04:04 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Respiratory syncytial virus bronchitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Immune Response and Safety of RSVPreF3 Vaccine in Adults 18-49 at Risk for Respiratory Syncytial Virus Compared to Adults 60 and Older https://clinicaltrials.eu/trial/study-on-the-immune-response-and-safety-of-rsvpref3-vaccine-in-adults-18-49-at-risk-for-respiratory-syncytial-virus-compared-to-adults-60-and-older/ Wed, 29 Apr 2026 15:05:36 +0000 https://clinicaltrials.eu/trial/study-on-the-immune-response-and-safety-of-rsvpref3-vaccine-in-adults-18-49-at-risk-for-respiratory-syncytial-virus-compared-to-adults-60-and-older/ This clinical trial is focused on studying a vaccine for the prevention of Respiratory Syncytial Virus (RSV) Infections. The vaccine being tested is called Arexvy, which is a powder and suspension for injection. It is designed to help the body build a defense against RSV, a virus that can cause respiratory illnesses, especially in people with certain health conditions.

The purpose of the study is to evaluate the immune response and safety of the RSVPreF3 OA investigational vaccine in adults aged 18 to 49 who are at increased risk for RSV disease, compared to older adults aged 60 and above. Participants will receive the vaccine through an injection into the muscle. The study will monitor the immune response to the vaccine and any side effects that may occur.

Participants will be observed over a period of time to assess how their bodies respond to the vaccine. The study aims to ensure that the vaccine is safe and effective for people who are at higher risk of severe RSV infections, such as those with chronic health conditions like Chronic Obstructive Pulmonary Disease (COPD), asthma, or diabetes. The study will help determine if the vaccine can provide protection against RSV in these groups.

]]> Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections https://clinicaltrials.eu/trial/study-on-the-immune-response-and-safety-of-rsvpref3-oa-vaccine-in-adults-aged-60-with-respiratory-syncytial-virus-infections/ Wed, 29 Apr 2026 15:05:32 +0000 https://clinicaltrials.eu/trial/study-on-the-immune-response-and-safety-of-rsvpref3-oa-vaccine-in-adults-aged-60-with-respiratory-syncytial-virus-infections/ This clinical trial is focused on studying a disease called Respiratory Syncytial Virus (RSV) infections, which can cause respiratory illnesses, especially in older adults. The study will use a vaccine known as Arexvy, which is designed to help the body build protection against RSV. This vaccine is given as an injection and contains a special protein from the virus, combined with an ingredient that helps boost the body’s immune response.

The purpose of the study is to evaluate how well the vaccine works and how safe it is for people aged 60 and above. Participants in the study will receive the vaccine at different times to see how their immune systems respond. Some participants will receive a single dose of the vaccine, while others will receive a revaccination dose before the RSV season. The study will monitor the immune response by measuring the levels of protective substances in the blood before and after vaccination.

Throughout the study, participants will be observed for any side effects or health changes. The study will also track any serious health events that occur after vaccination. This research aims to understand the best vaccination schedule to protect older adults from RSV infections effectively.

]]>